GLP-1 Compounding Crackdown: FDA Sends 10 Warning Letters in a Single Day

On February 20, 2026, FDA issued warning letters to 10 companies on the same day. Each letter focused on compounded GLP-1 drugs such as semaglutide and tirzepatide sold through telehealth platforms and compounding pharmacies.

For compliance teams that weren't watching closely, the first sign was a news headline. For others, it was a client call. Here's what actually happened.

What Triggered the GLP-1 Warning Letter Sweep

The root cause traces back to FDA's drug shortage list.

Semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, the active ingredient in Mounjaro and Zepbound, had appeared on FDA's shortage list. That shortage status affected how 503A and 503B compounders evaluated GLP-1 compounding.

When FDA removed these drugs from the shortage list, that exemption disappeared. Compounding pharmacies and telehealth platforms that continued to prepare and dispense compounded versions were now operating outside the permissible scope.

FDA responded with a coordinated group of letters.

The 10 Companies That Received FDA GLP-1 Warning Letters

All of the following received FDA warning letters on February 20, 2026. All letters are publicly available on FDA.gov:

Legal Entity	Doing Business As
Kare Solutions, LLC	Zappy
Strut Health, LLC	Strut
Peaks Curative, LLC	Peaks
Lean Rx, Inc.	SkinnyRx
Good Girl LLC	GoodGirlRX
Refills Health, LLC	Refills Health
Weightless Medical LLC	WeightCare
Ivim Services LLC	Ivim
Viv Health, Inc.	VIV RX
Premium Health Management Inc.	Premium Health

What an FDA Warning Letter Means

An FDA warning letter is an official notice that a company is in violation of regulations FDA enforces. It is:

• Public: FDA posts warning letters on FDA.gov, where investors, partners, competitors, and reporters can read them.
• Serious: FDA uses the letter to describe violations and request corrective action.
• Time-sensitive: companies usually need to respond within 15 business days.

A warning letter does not automatically result in a product recall or shutdown. But it does trigger a formal enforcement record, and failure to respond adequately can escalate to additional inspections, import alerts, injunctions, or seizures.

What This Signals for the Industry

Teams that monitored GLP-1 shortage status and FDA warning letters had more context for the February 20 action. Teams that checked FDA.gov only occasionally had less time to read the pattern.

A few patterns worth noting:

FDA sometimes moves in groups. When FDA identifies the same issue across an industry segment, several letters can appear close together. The shortage-list change gave this GLP-1 group a clear timeline.

Telehealth promotion sits close to the enforcement record. Companies in this space should watch FDA shortage-list changes, product claims, checkout paths, and pharmacy relationships together.

FDA.gov becomes the public record quickly. FDA often posts warning letters soon after issuance. A weekly source check gives teams a cleaner starting point than a rushed search after the story spreads.